

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Effects of Pegylated Filgrastim (PEG-G-CSF) Adjuvant on Improving Response to Hepatitis B Vaccine and HBs-Ab Serum Levels in Non-responder Chronic Hemodialysis Patients- A Randomized Double-Blind Clinical Trial

#### Protocol summary

##### Study aim

1) Determining the HBs-Ab serum levels and improving the response rate to the hepatitis B vaccine in hemodialysis patients receiving PEG-G-CSF adjuvant 2) Determining the improved response rate to the hepatitis B vaccine in hemodialysis patients receiving PEG-G-CSF adjuvant by age, sex, and underlying diseases

##### Design

A controlled, double-blind, randomized, phase 2 clinical trial will be conducted on 80 hemodialysis patients. The block randomization method and SAS 9.3 software will be used for randomization.

##### Settings and conduct

All hemodialysis centers affiliated with SUMS will participate in this trial. Participants, outcome assessors, and statisticians will be blinded to treatment allocation. Randomization will be computer-generated by an independent data administrator.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age range between 18-70 years  
Dialysis adequacy 3 times a week  
Negative serology for HBsAg, total anti-HBC, anti HCV, HIV  
Receiving 3 IM doses of HBV vaccination and HBS-Ab titer <10 IU/L (non-responder patients)  
Exclusion criteria: Positive serology for HBsAg, total anti-HBC, anti HCV, HIV  
Prior use of any immunomodulatory agents like steroids/vaccine adjuvants and blood transfusion in last 6 months  
Scheduled to have kidney transplantation within 3 months

##### Intervention groups

Non-responder Hemodialysis patients will be randomized in a 1:1 ratio into 2 groups: Control Group received three booster dose of HBV vaccine IM (0, 2nd, 6th months), Adjuvant Group received a dose 6 mg/0.6 mL subcutaneous PEG-G-CSF (PegaGen®, CinnaGen) 24 hours before first booster dose of HBV vaccine IM, and

received other two booster dose in the 2nd and 6th months. HBS-Ab was measured 1 month after the last two boosters (3rd, 7th months).

##### Main outcome variables

Antibody to hepatitis B surface antigen  
Response rates to vaccine  
Total leukocyte and neutrophile count

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20090701002113N4**

Registration date: **2025-12-19, 1404/09/28**

Registration timing: **prospective**

Last update: **2025-12-19, 1404/09/28**

Update count: **0**

##### Registration date

2025-12-19, 1404/09/28

##### Registrant information

##### Name

Jamshid Roozbeh

##### Name of organization / entity

Shiraz university of medical sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 1235 6400

##### Email address

roozbehj@sums.ac.ir

##### Recruitment status

**recruiting**

##### Funding source

**Expected recruitment start date**

2025-12-31, 1404/10/10

**Expected recruitment end date**

2026-08-01, 1405/05/10

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Effects of Pegylated Filgrastim (PEG-G-CSF) Adjuvant on Improving Response to Hepatitis B Vaccine and HBs-Ag Serum Levels in Non-responder Chronic Hemodialysis Patients- A Randomized Double-Blind Clinical Trial

**Public title**

PEG-G-CSF in Non-responder Hemodialysis Patients HBs-Vaccination

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

Age range between 18 and 70 years Patients with dialysis adequacy 3 times a week Patients with negative serology for HBsAg, total anti-HBC, anti HCV, HIV 1 and 2 Receiving 3 IM doses of HBV vaccination and HBS-Ab titer <10 IU/L (non-responder patients) Patients of chronic renal failure with serum creatinine >2.0 mg/dL, Glomerular filtration rate (GFR) <60 mL/min on hemodialysis (HD)

**Exclusion criteria:**

Patients with positive serology for HBsAg, total anti-HBC, anti HCV, HIV 1 and 2 Prior use of any immunomodulatory agents like steroids/vaccine adjuvants in last 6 months Receiving blood transfusion in previous 6 months Scheduled to have kidney transplantation within 3 months History of active cancer or active infection under treatment Pregnancy, childbearing potential during the study period, or breastfeeding

**Age**From **18 years** old to **70 years** old**Gender**

Both

**Phase**

2

**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor
- Data analyser

**Sample size**Target sample size: **80****Randomization (investigator's opinion)**

Randomized

**Randomization description**

Randomization will be performed by an independent statistician using a computerized random number generator via the SAS 9.3 software block randomization

method (SAS Institute, Cary, NC, USA). Eligible participants will be randomly assigned 1:1 to a control group or a treatment group. All individuals who meet the inclusion/exclusion criteria at the first visit will be assigned to a group using the blocked randomization method, based on the allocation codes. Each patient will be assigned a unique study number. An independent data administrator who is not involved in clinical practice or patient recruitment will generate the randomization sequence.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, a double-blind design will be implemented. Participants, researchers, outcome assessors, and statisticians will remain unaware of the treatment allocation to prevent any bias resulting from expectations or preconceived notions. To ensure this, randomization lists will be generated by an independent data manager who is not involved in the study, using a computerized system. After generation, these lists will remain concealed from the researchers and other study team members and will be kept strictly confidential. Treatment allocation to participants will be done automatically by the software in a centralized manner, without human intervention. As a result, none of the researchers or outcome assessors will have knowledge of the treatment assigned to the participants throughout the study, and this process will remain confidential until the final analysis and result reporting.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Research Ethics Committees of School of Medicine - Shiraz University of Medical Sciences

**Street address**

7th floor, University Central Building, Zand street

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Approval date**

2024-06-16, 1403/03/27

**Ethics committee reference number**

IR.SUMS.MED.REC.1403.176

## Health conditions studied

### 1

#### Description of health condition studied

End-stage Kidney disease

#### ICD-10 code

N18.6

#### ICD-10 code description

End stage renal disease

## Primary outcomes

### 1

#### Description

HBs-Ab serum levels

#### Timepoint

Before first vaccin booster and one month after the last two vaccine boosters (3rd, 7th months)

#### Method of measurement

HBs-Ab serum levels will be measured by ELISA methods. 5 ml of blood will be collected in K2-EDTA tubes and HBs-Ab will be measured before PEG-G-CSF and the first vaccine booster injection, and 1 month after the last two boosters.

### 2

#### Description

Response rate to hepatitis B vaccine

#### Timepoint

One month after the third booster dose (month 7 of the study period)

#### Method of measurement

Calculating the percentage change from baseline antibody levels

## Secondary outcomes

### 1

#### Description

Total leukocyte count

#### Timepoint

One month after the third booster dose (month 7 of the study period)

#### Method of measurement

Performing CBC Diff test for patients

### 2

#### Description

Neutrophil count

#### Timepoint

One month after the third booster dose (month 7 of the study period)

#### Method of measurement

Performing CBC Diff test for patients

## Intervention groups

### 1

#### Description

Intervention group: will receive a dose of 6 mg/0.6 mL subcutaneous PEG-G-CSF 24 hours before the first booster dose of HBV vaccine IM, and receive the other two booster doses in the 2nd and 6th months.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: will receive three booster dose of HBV vaccine IM (0, 2nd, 6th months)

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Namazi Teaching Hospital

##### Full name of responsible person

Jamshid Roozbeh

##### Street address

Namazi Square, Zand Street

##### City

Shiraz

##### Province

Fars

##### Postal code

7193613311

##### Phone

+98 71 3647 4332

##### Fax

+98 71 3647 4326

##### Email

nemazee\_inf@sums.ac.ir

##### Web page address

<https://namazi.sums.ac.ir>

### 2

#### Recruitment center

##### Name of recruitment center

Shahid Faghihi Hospital

##### Full name of responsible person

Ramin Radmehr

##### Street address

Karim Khan Zand Street

##### City

Shiraz

##### Province

Fars

##### Postal code

7134844119

##### Phone

+98 71 3235 1087

**Email**

faghiihsp@sums.ac.ir

## Sponsors / Funding sources

### 1

**Sponsor**

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Hamid Mohammadi

**Street address**

7th Floor, SUMS Central Building, Karim Khan Zand Street

**City**

Shiraz

**Province**

Fars

**Postal code**

7134814336

**Phone**

+98 71 3212 2430

**Email**

vcrdep@sums.ac.ir

**Web page address**

<https://research.sums.ac.ir/office>

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Shiraz University of Medical Sciences

**Proportion provided by this source**

30

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

### 2

**Sponsor**

**Name of organization / entity**

CinnaGen

**Full name of responsible person**

Mehdi Ahmadi

**Street address**

No. 34, Sepehr Street, Farahzadi Boulevard, West Town

**City**

Shiraz

**Province**

Fars

**Postal code**

3165933155

**Phone**

+98 66 7033 4263

**Email**

info@cinnagen.com

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

CinnaGen

**Proportion provided by this source**

70

**Public or private sector**

Private

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Industry

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Fatemeh Masjedi

**Position**

Professor of Nephrology

**Latest degree**

Specialist

**Other areas of specialty/work**

Nephrology

**Street address**

6th floor, Nephro-Urology Research Center, Research Tower, Khalili Street

**City**

Shiraz

**Province**

Fars

**Postal code**

7193635899

**Phone**

+98 71 3628 1528

**Fax**

**Email**

roozbehj@hotmail.com

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Fatemeh Masjedi

**Position**

Assistant Professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Physiology

**Street address**

6th floor, Nephro-Urology Research Center, Research Tower, Khalili Street

**City**

Shiraz

**Province**

Fars

**Postal code**

7193635899

**Phone**

+98 71 3628 1528

**Email**

masjedi\_f@sums.ac.ir

0098 71 5330505

**Email**

srahmanian59@yahoo.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All data is potentially shareable after de-identifying individuals.

**When the data will become available and for how long**

Access period starts 6 months after results are published.

**To whom data/document is available**

Only for researchers working in academic and scientific institutions.

**Under which criteria data/document could be used**

Reporting data based on our analyses in the form of books, reviews, and meta-analyses.

**From where data/document is obtainable**

Contact us with the following email:  
masjedi\_f@sums.ac.ir

**What processes are involved for a request to access data/document**

Maximum two weeks after email sending and sufficient explanation of how the data will be used.

**Comments****Person responsible for updating data****Contact****Name of organization / entity**

Jahrom University of Medical Sciences

**Full name of responsible person**

Sara Rahmanian

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Nephrology

**Street address**

Motahari Street

**City**

Jahrom

**Province**

Fars

**Postal code**

۴۶۱۹۹۷۴۱۴۸

**Phone**